Most cases of leukopenia are associated with a low number of granulocytes.
Decreased production of granulocytes may be caused by marrow failure, infiltration of the marrow by leukemic cells or metastatic cancer cells, suppression of granulocyte production by certain drugs, and vitamin B12 or folate deficiency.
There may be an accelerated removal of granulocytes following exposure to certain drugs, as part of an autoimmune disorder, in certain infections, or from splenic sequestration of granulocytes.
Suggested Additional Lab Testing
Most important test: WBC count and differential
Peripheral blood smear and bone marrow aspirate, with or without bone marrow biopsy, is informative in the diagnosis of certain leukopenias.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Moving Targets: Off-Label Prescribing of Targeted Therapies
- New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma
- 2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
- Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer
- Immunotherapy Combo in Head and Neck Cancer Shows Activity in Phase 2 Trial
- Nutraceuticals/Supplements and Cancer Prevention: All Hype?
- Plastics and Cancer
- Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition
- Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Study Adds More Evidence to Support Active Surveillance as the Standard of Care for Certain Desmoid Tumors
- Palliative Care and Survivorship
- Dosing Schedule May Be Key to Optimal Administration of Milademetan for Sarcoma Subtype
- Phase 2 Trial of Abemaciclib in Dedifferentiated Liposarcoma Meets Primary End Point
- Mouse-Dog-Human Preclinical Cancer Model for Osteosarcoma Proposed